Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors
The nomogram models effectively predict irAEs in NPC patients treated with PD-L1 inhibitors. Early identification of patients with elevated PD-L1, abnormal FT4, Na, or irregular lymphocyte counts allows for closer monitoring and personalized treatment, potentially improving outcomes. Further research is required to confirm these findings across other cancer types and therapies.
Authors
- Yiyan Pei (ORCID: https://orcid.org/0000-0003-3293-6236)
- Ping Ai (ORCID: https://orcid.org/0000-0002-0169-0926)
- Zheran Liu (ORCID: https://orcid.org/0000-0002-4848-4951)
- Shihong Xu
- Junyou Ge
- Youneng Wei
- Xingchen Peng (ORCID: https://orcid.org/0000-0001-7042-718X)
- Yan Qing
- Ye Chen (ORCID: https://orcid.org/0000-0002-7964-7899)
- Mengyuan Liu (ORCID: https://orcid.org/0000-0002-6415-9788)
- Shuangshuang He (ORCID: https://orcid.org/0000-0002-4402-1642)
Institutions
- Sichuan University (CN)
- Kelun Group (China) (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-13
- DOI
- https://doi.org/10.3389/fonc.2025.1539514
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00